|Table of Contents|

Diagnostic value of thioredoxin reductase in cervical carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
639-642
Research Field:
Publishing date:

Info

Title:
Diagnostic value of thioredoxin reductase in cervical carcinoma
Author(s):
Wang Lili; Wu Wei; Wu Xiaoyan; Zhang Jinye
Department of Clinical Aboratory,Nantong Tumor Hospital,Jiangsu Nantong 226361,China.
Keywords:
thioredoxin reductase（TR); cervical cancer; CEA; CA125; SCC
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2020.04.027
Abstract:
Objective：To analyze the diagnostic value of TR in cervical carcinoma.Methods:Plasma was collected from 217 cases of pathologically confirmed cervical cancer patients in our hospital from October 2017 to May 2018.All the patients were initially diagnosed and no other treatment was performed before the operation.Blood plasma of 50 benign cervical lesions and 60 healthy controls were collected too.TR concentration was detected by enzyme kinetics method,all completed by Kaixi Medical Detection Company.CEA,CA125 and SCC were detected by Roche electrochemical luminescence method.SPSS 19.0 statistical software was used for analysis.TR was compared between cervical cancer and benign lesions and healthy control group using mann-whitney U test.The correlation between plasma TR and pathological features of patients with cervical cancer was examined by the nonparametric rank sum test.Spearman correlation was used to analyze the relationship between plasma TR and CEA,CA125 and SCC in cervical cancer patients,and ROC curve and AUC（95%CI) were used to evaluate their diagnostic efficacy as a diagnostic indicator.Results:The relative expression of TR was 6.78（4.73,9.38)U/ml,3.69（2.65,4.99)U/ml and 3.26（2.66,4.28)U/ml in cervical cancer,benign lesions and healthy control group,respectively.The TR content of cervical cancer was significantly higher than that of benign lesions and healthy control group,and the differences were statistically significant（P＜0.001).There was no significant difference in TR content between benign lesions and healthy controls（P=0.089).According to the nonparametric rank sum test,the content of plasma TR in patients with cervical cancer is independent of age,type and stage（P＞0.05).The results showed that the sensitivity and accuracy of TR were 75.1% and 79.8%,respectively,higher than CEA,CA125 and SCC.The diagnostic value of TR,CEA,CA125 and SCC for cervical cancer was 0.893,0.510,0.769 and 0.550,respectively,according to AUC.The highest AUC value of the combined diagnosis of the four indicators was 0.946.Conclusion:The plasma concentration of TR in patients of cervical cancer is significantly higher than that of the benign lesions group and the healthy control group,and the diagnostic efficiency of TR to cervical cancer is higher than that of CEA,CA125 and SCC.The combined detection efficiency of the four indicators is the highest.TR can be used as a good diagnostic indicator for cervical cancer.

References:

[1]Chen W,Zheng R,Zhang S,et al.Report of cancer incidence and mortality in China,2010［J］.Ann Transl Med,2014,2（7):61.
[2]Huang Z,Zheng Y,Wen W,et al.Incidence and mortality of gynaecological cancers:Secular trends in urban Shanghai,China over 40 years［J］.Eur J Cancer,2016,08（63):1-10.
[3]De Sanjose,S Quint WG,Alemany L,et al.Human papilloma virus genotype attribution in invasive cervical cancer:A retrospective cross-sectional worldwide study［J］.Lancet Oncol,2010,11(11):1048-1056.
[4]De Freitas AC,Gurgel AP,Chagas BS,et al.Susceptibility to cervical cancer:An overview［J］.Gynecol Oncol,2012,126（2):304-311.
[5]Uyar D,Rader J.Genomics of cervical cancer and the role of human papillomavirus pathobiology［J］.Clin Chem,2014,60(1):144-146.
[6] Federico De Marco,Elona Bucaj,Cesira Foppoli,et al.Oxidative stress in HPV-driven viral carcinogenesis:Redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues［J］.PLoS One,2012,7(3):1-13.
[7]LIU P.Evaluation of clinical epidemiology of cervical cancer of 13 years in mainland China ［J］.Chinese Journal of Applied Gynecology and Obstetrics,2018,34(1):41-45.［刘萍.中国大陆13年宫颈癌临床流行病学大数据评价［J］.中国实用妇科与产科杂志,2018,34(1):41-45.］
[8] Fink EE,Mannava S,Bagati A,et al.Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells［J］.Leukemia,2016,30(1):104-111.
[9]Muri J,Heer S,Matsushita M,et al.The thioredoxin-1 system is essential for fueling DNA synthesis during T-cell metabolic reprogramming and proliferation［J］.Nat Commun,2018,9(1):1851-1867.
[10]Li K,Zheng Q,Chen X,et al.Isobavachalcone induces ROS-mediated apoptosis via targeting thioredoxin reductase 1 in human prostate cancer PC-3 cells［R/OL］.(2018-10-16) ［2018-11-20］.http://doi.org/10.1155/2018/1915828.
[11]Liu Y,Zhao Y,Wei Z,et al.Targeting thioredoxin system with an organosulfur compound,diallyl trisulfide（DATS),attenuates progression and metastasis of triple-negative breast cancer（TNBC)［J］.Cell Physiol Biochem,2018,50(5):1945-1963.
[12] Li C,Peng Y,Mao B,et al.Thioredoxin reductase:A novel,independent prognostic marker in patients with hepatocellular carcinoma［J］.Oncotarget,2015,6(19):17792-17804.
[13]BU Lina,LIN Yurong,LIU Yanfeng,et al.Expression and prognosis of TrxR2 in non－small cell lung cancer［J］.Modern Oncology,2017,25(20):3245-3248.［卜丽娜,林玉蓉,刘延峰,等.硫氧还蛋白还原酶－2在非小细胞肺癌中的表达及预后［J］.现代肿瘤医学,2017,25(20):3245-3248.］
[14]Erdi F,Kaya B,Esen H,et al.New clues in the malignant progression of glioblastoma:Can the thioredoxin system play a role［J］?Turkish Neurosurgery,2018,28(1):7-12.
[15]Esen H,Erdi F,Kaya B,et al.Tissue thioredoxin reductase-1 expression in astrocytomas of different grades［J］.Journal of Neuro-oncology,2015,121(3):451-458.

Memo

Memo:
-
Last Update: 2019-12-26